Title: Cardiologists Break Down Key Heart Health Insights for Patients

Cardiologists are reevaluating the routine use of daily low-dose aspirin for primary prevention of heart disease, citing growing evidence that its risks may outweigh benefits for many adults without existing cardiovascular disease.

Recent guidance from major health organizations reflects a shift away from blanket recommendations for aspirin use in otherwise healthy individuals. The U.S. Preventive Services Task Force (USPSTF) updated its stance in 2022, advising against initiating low-dose aspirin for primary prevention in adults aged 60 and older due to increased risk of gastrointestinal bleeding and hemorrhagic stroke. For adults aged 40 to 59 with a 10% or greater 10-year cardiovascular disease risk, the decision should be individualized and made in consultation with a clinician.

This change is grounded in clinical trial data showing that while aspirin can reduce the risk of heart attack and ischemic stroke, it simultaneously raises the likelihood of major bleeding events. A 2019 meta-analysis published in The Lancet found that among individuals without cardiovascular disease, aspirin use was associated with a 11% lower risk of cardiovascular events but a 43% higher risk of major bleeding.

Cardiologists emphasize that aspirin therapy remains appropriate for secondary prevention — that is, for individuals who have already experienced a heart attack, stroke, or have diagnosed cardiovascular disease. In these cases, the benefits of preventing recurrent events generally outweigh the bleeding risks.

“We’ve moved from a one-size-fits-all approach to a more personalized assessment,” said a cardiologist interviewed during the TOI Medithon 2025 discussions on heart health across generations. “For younger adults without risk factors, lifestyle modifications — such as diet, exercise, and blood pressure control — offer safer and more sustainable protection than routine aspirin use.”

The discussions at TOI Medithon 2025 highlighted that misconceptions about aspirin persist, particularly among younger adults who may begin taking it based on outdated advice or anecdotal reports. Experts urged patients to consult healthcare providers before starting or stopping any preventive medication, especially as individual risk profiles vary widely based on factors like age, blood pressure, cholesterol levels, diabetes status, and smoking history.

Alternative strategies for reducing cardiovascular risk continue to be supported by strong evidence. These include adopting a plant-rich diet low in processed foods and added sugars, engaging in regular physical activity tailored to individual capacity, maintaining healthy weight and sleep patterns, avoiding tobacco, and managing stress. Routine screening for blood pressure, lipids, and glucose remains a cornerstone of early detection and intervention.

Ongoing research continues to refine understanding of who may still benefit from low-dose aspirin. Some studies suggest potential advantages in specific subgroups, such as those with elevated coronary artery calcium scores or certain inflammatory markers, but these findings are not yet sufficient to support broad recommendations.

the message from cardiologists is clear: aspirin is not a harmless supplement, and its use for heart disease prevention should be guided by individualized risk assessment rather than habit or assumption. Patients are encouraged to discuss their cardiovascular risk and prevention options with their healthcare team to make informed, evidence-based decisions.